Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers.

Originally posted here:
Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Share

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

Link:
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Share

Ten Genesis HealthCare facilities named recipients of Silver – Commitment to Quality Award

Genesis HealthCare, one of the nation’s largest providers of post-acute care, today announced that 10 of its Centers have been recognized as 2015 recipients of the Silver – Commitment to Quality Award for dedication to improving the lives of patients and residents through quality care.

Follow this link:
Ten Genesis HealthCare facilities named recipients of Silver – Commitment to Quality Award

Share

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma’s Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

View the original here:
SutroVax completes $22 million Series A financing

Share

EGPAF calls for prioritizing HIV treatment among children

As the HIV/AIDS community gathers for the International AIDS Society Conference in Vancouver, Canada, the Elizabeth Glaser Pediatric AIDS Foundation joins the Vancouver Consensus in calling for universal treatment for all people living with HIV, regardless of CD4 count. Providing treatment for everyone living with HIV will be a paradigm shift in HIV treatment and prevention efforts, particularly for children living with HIV, and will save millions of lives.

View article:
EGPAF calls for prioritizing HIV treatment among children

Share

Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Beckman Coulter Life Sciences today announces an expansion of its CARES (Cellular Accessible Retroviral Evaluation Systems) Initiative at the 2015 International AIDS Society (IAS) Conference, being held at the Vancouver Convention Centre from July 19-22, 2015 in Vancouver, Canada. CARES focuses on providing innovative solutions for the monitoring of HIV and AIDS treatment in Africa.

View article:
Beckman Coulter announces expansion of Cellular Accessible Retroviral Evaluation Systems Initiative at International AIDS Society 2015

Share